AU2018360045B2 - Monoclonal antibody NEO-201 for the treatment of human carcinomas - Google Patents

Monoclonal antibody NEO-201 for the treatment of human carcinomas Download PDF

Info

Publication number
AU2018360045B2
AU2018360045B2 AU2018360045A AU2018360045A AU2018360045B2 AU 2018360045 B2 AU2018360045 B2 AU 2018360045B2 AU 2018360045 A AU2018360045 A AU 2018360045A AU 2018360045 A AU2018360045 A AU 2018360045A AU 2018360045 B2 AU2018360045 B2 AU 2018360045B2
Authority
AU
Australia
Prior art keywords
antibody
neo
cells
patient
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018360045A
Other languages
English (en)
Other versions
AU2018360045A1 (en
Inventor
Philip M. ARLEN
Kwong Y. Tsang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Precision Biologics Inc
Original Assignee
Precision Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Precision Biologics Inc filed Critical Precision Biologics Inc
Publication of AU2018360045A1 publication Critical patent/AU2018360045A1/en
Application granted granted Critical
Publication of AU2018360045B2 publication Critical patent/AU2018360045B2/en
Priority to AU2025205420A priority Critical patent/AU2025205420A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2018360045A 2017-11-03 2018-11-02 Monoclonal antibody NEO-201 for the treatment of human carcinomas Active AU2018360045B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025205420A AU2025205420A1 (en) 2017-11-03 2025-07-14 Monoclonal antibody NEO-201 for the treatment of human carcinomas

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762581380P 2017-11-03 2017-11-03
US62/581,380 2017-11-03
US201762592778P 2017-11-30 2017-11-30
US62/592,778 2017-11-30
PCT/US2018/059039 WO2019090134A1 (en) 2017-11-03 2018-11-02 Monoclonal antibody neo-201 for the treatment of human carcinomas

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025205420A Division AU2025205420A1 (en) 2017-11-03 2025-07-14 Monoclonal antibody NEO-201 for the treatment of human carcinomas

Publications (2)

Publication Number Publication Date
AU2018360045A1 AU2018360045A1 (en) 2020-05-21
AU2018360045B2 true AU2018360045B2 (en) 2025-04-17

Family

ID=66332711

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018360045A Active AU2018360045B2 (en) 2017-11-03 2018-11-02 Monoclonal antibody NEO-201 for the treatment of human carcinomas
AU2025205420A Pending AU2025205420A1 (en) 2017-11-03 2025-07-14 Monoclonal antibody NEO-201 for the treatment of human carcinomas

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025205420A Pending AU2025205420A1 (en) 2017-11-03 2025-07-14 Monoclonal antibody NEO-201 for the treatment of human carcinomas

Country Status (7)

Country Link
US (2) US11767367B2 (enExample)
EP (1) EP3735423A4 (enExample)
JP (3) JP7437307B2 (enExample)
CN (3) CN119587690A (enExample)
AU (2) AU2018360045B2 (enExample)
CA (1) CA3083467A1 (enExample)
WO (1) WO2019090134A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019221544B2 (en) * 2018-02-13 2025-07-10 Precision Biologics, Inc. Methods and compositions for targeting Treg cells
CN115678854A (zh) * 2021-07-29 2023-02-03 上海中医药大学 一种基因工程细胞及其制备方法和应用
CN119053622A (zh) * 2022-04-12 2024-11-29 盛禾(中国)生物制药有限公司 一种抗ceacam5和ceacam6抗体及其应用
CN116699135B (zh) * 2022-04-29 2025-11-07 中国医学科学院肿瘤医院 癌症免疫治疗靶标和诊断、预后预测生物标志物的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130189268A1 (en) * 2010-06-22 2013-07-25 Precision Biologics, Inc. Colon and pancreas cancer specific antigens and antibodies
WO2014106176A1 (en) * 2012-12-28 2014-07-03 Precision Biologics, Inc. Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3160498T3 (pl) * 2014-06-30 2022-02-21 Altor Bioscience Corporation Cząsteczki na bazie IL-15 i sposoby ich zastosowania
WO2018218230A1 (en) * 2017-05-26 2018-11-29 Etubics Corporation Combination immunotherapies comprising il-15 superagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130189268A1 (en) * 2010-06-22 2013-07-25 Precision Biologics, Inc. Colon and pancreas cancer specific antigens and antibodies
WO2014106176A1 (en) * 2012-12-28 2014-07-03 Precision Biologics, Inc. Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Arlen, P. 'The Discovery and Development of Novel Monoclonal Antibodies Targeting Neoantigens', Precision Biologics, (2017-02-01) *
Neuman, M. et al., 'Abstract 1496: Identification of target and cytotoxicity of novel monoclonal antibody NEO-201 in ovarian and uterine cancer subtypes', Cancer Research, (2016), vol. 76, doi: 10.1158/1538-7445.AM2016-1. *
Neuman, M. et al., 'Identification of target and cytotoxicity of novel monoclonal antibody NEO-201 in ovarian and uterine cancer subtypes', Gynecologic Oncology, (2016-06-01), vol. 141, pages 95 - 96, doi: 10.1016/J.YGYNO.2016.04.264 *
Van Audenaerde, J. et al., 'Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells', Oncotarget, (2017-05-25), vol. 8, no. 34, pages 56968-56979, doi: 10.18632/oncotarget.18185. *

Also Published As

Publication number Publication date
AU2025205420A1 (en) 2025-07-31
CN120860200A (zh) 2025-10-31
JP2024010054A (ja) 2024-01-23
JP7712338B2 (ja) 2025-07-23
US11767367B2 (en) 2023-09-26
JP2025148435A (ja) 2025-10-07
US20200362053A1 (en) 2020-11-19
EP3735423A1 (en) 2020-11-11
CN111670199A (zh) 2020-09-15
US20240101702A1 (en) 2024-03-28
JP7437307B2 (ja) 2024-02-22
CN119587690A (zh) 2025-03-11
WO2019090134A1 (en) 2019-05-09
CN111670199B (zh) 2025-06-17
JP2021502416A (ja) 2021-01-28
CA3083467A1 (en) 2019-05-09
AU2018360045A1 (en) 2020-05-21
EP3735423A4 (en) 2021-02-24

Similar Documents

Publication Publication Date Title
AU2017228055B2 (en) Antibodies specific to human poliovirus receptor (PVR)
JP7573365B2 (ja) 癌の併用療法
TWI645858B (zh) 反應b7-h3之抗體、其免疫活性片段及使用
US20240101702A1 (en) Monoclonal antibody neo-201 for the treatment of human carcinomas
US20240400714A1 (en) Methods and compositions for targeting treg cells
Fantini et al. Preclinical characterization of a novel monoclonal antibody NEO-201 for the treatment of human carcinomas
KR20240161985A (ko) 친화도가 성숙된 mica 항체 및 이의 응용
US20240384003A1 (en) Methods and compositions for treating hematological malignancies
HK40001896B (en) Antibodies specific to human poliovirus receptor (pvr)
HK40001896A (en) Antibodies specific to human poliovirus receptor (pvr)

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)